

SECTION-1: Identification of the substance / mixture and the company / undertaking

Catalogue Number	CS-CB-00056
Product Name	Lemborexant
CAS No.	1369764-02-2
Category	API
Synonyms	(1R,2S)-2-[[[(2,4-Dimethyl-5-pyrimidinyl)oxy]methyl]-2-(3-fluorophenyl)-N-(5-fluoro-2-pyridinyl)cyclopropanecarboxamide
Brand	Clearsynth Labs Ltd.
Identified uses	Laboratory Chemicals
Uses advised against	Not available
Company	Clearsynth Labs Ltd. Mumbai, India
Emergency Phone #	+91-22-245045900
REACH No.	Not available

SECTION 2: Hazards identification

Disclaimer: This is sample MSDS. Please email sales@clearsynth.com for more details.

2.1 Classification of the substance or mixture-Regulation (EC) No 1272/2008:

Not available

2.2 Label Elements

Signal Word: Not available

Not available

Hazard Statement(s)

Code	Statement
Not available	Not available

Precautionary Statement(s)

Code	Statement
Not available	Not available

SECTION 3: Composition / information on ingredients

3.1 Substance

Component : Lemborexant

CAS Number : 1369764-02-2

Molecular Formula : C₂₂H₂₀F₂N₄O₂

Molecular Weight : 410.42

Parent Chemical : Lemborexant

Synonyms : (1R,2S)-2-[[[(2,4-Dimethyl-5-pyrimidinyl)oxy]methyl]-2-(3-fluorophenyl)-N-(5-fluoro-2-pyridinyl)cyclopropyl]anecarboxamide

Concentration : Not available

SECTION 4: First aid measures

SECTION 4: First-aid measures

4.1 Description of first aid measures

- General advice: Seek medical attention if symptoms occur or persist. Show this SDS to the physician.
- Inhalation: Move person to fresh air. If breathing is difficult, seek medical attention.
- Skin contact: Wash with plenty of soap and water. Remove contaminated clothing and wash before reuse. Get medical attention if irritation develops.
- Eye contact: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do. Continue rinsing. Seek medical attention if irritation persists.
- Ingestion: Rinse mouth. Do NOT induce vomiting unless directed by medical personnel. Seek medical attention.

4.2 Most important symptoms and effects, both acute and delayed

- Not available.

4.3 Indication of any immediate medical attention and special treatment needed

- Treat symptomatically. No data available.

SECTION 5: Firefighting measures

SECTION 5: Fire-fighting measures

5.1 Extinguishing media

- Suitable extinguishing media: Water spray, alcohol-resistant foam, dry chemical, carbon dioxide.
- Unsuitable extinguishing media: Not available.

5.2 Special hazards arising from the substance or mixture

- Hazardous combustion products: Not available. May form irritating and/or toxic fumes upon combustion.

5.3 Advice for firefighters

- Wear self-contained breathing apparatus (SCBA) and full protective gear.
- Use water spray to cool unopened containers.
- Avoid inhalation of combustion products.

SECTION 6: Accidental release measures

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

- Avoid breathing dust. Avoid contact with skin and eyes.
- Use appropriate personal protective equipment (see Section 8).
- Ensure adequate ventilation.

6.2 Environmental precautions

- Prevent further leakage or spillage if safe to do so.
- Avoid release to the environment. Do not allow to enter drains/surface waters/groundwater.

6.3 Methods and material for containment and cleaning up

- Avoid generating dust.
- Collect spillage using methods that minimize dust generation (e.g., damp wipe, HEPA-filtered vacuum).
- Place in a suitable, closed container for disposal.

6.4 Reference to other sections

- See Section 8 for exposure controls/personal protection and Section 13 for disposal considerations.

SECTION-7: Handling and storage

SECTION 7: Handling and storage

7.1 Precautions for safe handling

- Handle in accordance with good industrial hygiene and safety practice.
- Avoid formation of dust and aerosols.
- Avoid contact with skin, eyes, and clothing. Avoid breathing dust.
- Use with adequate local exhaust ventilation.

7.2 Conditions for safe storage, including any incompatibilities

- Store in tightly closed container.
- Store in a cool, dry, well-ventilated place.
- Protect from moisture. Protect from incompatible materials.
- Incompatible materials: Not available.

7.3 Specific end use(s)

- API / laboratory and research use. Specific uses not available.

SECTION 8: Exposure controls / personal protection

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

- Occupational exposure limits: No data available.
- Biological limit values: No data available.

8.2 Exposure controls

- Engineering controls: Use local exhaust ventilation or other engineering controls to maintain airborne levels below applicable exposure limits (if established). Provide eyewash station and safety shower.
- Personal protective equipment (PPE):
 - Eye/face protection: Safety glasses with side shields or chemical goggles.
 - Skin protection: Protective gloves (material not available). Wear lab coat or protective clothing.
 - Respiratory protection: If dust/aerosol generation is possible or ventilation is inadequate, use a NIOSH-approved particulate respirator (type not available).

- Hygiene measures: Wash hands after handling. Do not eat, drink, or smoke when using this product. Remove contaminated clothing and wash before reuse.
- Environmental exposure controls: Avoid release to the environment.

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Test	Result
Appearance	No data available
IR spectrum	No data available
pH	No data available
Solubility	No data available

Property	Value
a) Physical State	No data available
b) Color	No data available
c) Odor	No data available
d) pH	No data available
e) Vapour Pressure	No data available
f) Viscosity	No data available
g) Initial Boiling Point and boiling range	No data available
h) Melting Point / Freezing Point	No data available
i) Auto Ignition Temperature	No data available
j) Flash Point	No data available
k) Explosion Limit, Lower	No data available
l) Explosion Limit, Upper	No data available
m) Decomposition Temperature	No data available
n) Loss on Drying	No data available
o) Relative Density	No data available
p) Solubility (in DMSO)	No data available

Property	Value
q) Oxidizing Properties	No data available

SECTION 10: Stability and reactivity

SECTION 10: Stability and reactivity

10.1 Reactivity

- No data available.

10.2 Chemical stability

- Stable under recommended storage conditions.

10.3 Possibility of hazardous reactions

- No data available.

10.4 Conditions to avoid

- Avoid excessive heat. Avoid dust generation. Other conditions: Not available.

10.5 Incompatible materials

- Not available.

10.6 Hazardous decomposition products

- Not available. May produce irritating and/or toxic fumes upon decomposition/combustion.

SECTION 11: Toxicological information

11.1 Information on toxicological effects

- Acute toxicity: Clinical evidence to support toxic doses of lemborexant in humans is scarce. In at least one clinical study, 7.5 times the recommended dose of lemborexant was given to healthy human subjects resulting in dose-dependent increases of somnolence frequency, providing little information regarding toxicity. There is no specific antidote to lemborexant overdose. In the case of a suspected overdose, the protocol of any drug overdose should be followed, with close monitoring from a medical professional.

- Skin corrosion/irritation: No data available.
- Serious eye damage/eye irritation: No data available.
- Respiratory or skin sensitization: No data available.
- Germ cell mutagenicity: No data available.
- Carcinogenicity: No data available.
- Reproductive toxicity: No data available.
- STOT-single exposure: No data available.
- STOT-repeated exposure: No data available.
- Aspiration hazard: No data available.

Likely routes of exposure

- No data available.

Symptoms related to the physical, chemical and toxicological characteristics

- In several clinical trials, lemborexant was found to be well tolerated, with serum ALT elevations above 3 times the upper limit of normal in less than 1% of treated subjects and with similar rates in placebo recipients. The elevations were transient and asymptomatic, none required dose modification or discontinuation, and none were associated with a simultaneous elevation in serum bilirubin. Thus, in the registration trials of lemborexant, there were no reports

of clinically apparent liver injury. Since its approval and more widespread use, lemborexant has been available has not been implicated in causing cases of clinically apparent liver injury. Likelihood score: E (unlikely cause of clinically apparent liver injury).

SECTION 12: Ecological information

SECTION 12: Ecological information

12.1 Toxicity

- No data available.

12.2 Persistence and degradability

- No data available.

12.3 Bioaccumulative potential

- No data available.

12.4 Mobility in soil

- No data available.

12.5 Results of PBT and vPvB assessment

- Not available.

12.6 Endocrine disrupting properties

- No data available.

12.7 Other adverse effects

- No data available.

SECTION 13: Disposal considerations

SECTION 13: Disposal considerations

13.1 Waste treatment methods

- Dispose of contents/container in accordance with local/regional/national/international regulations.

- Do not discharge to drains.

- Contaminated packaging: Dispose of as unused product or according to local requirements.

- Waste code: Not available.

SECTION 14: Transport information

SECTION 14: Transport information

- UN number: Not available.

- UN proper shipping name: Not available.

- Transport hazard class(es): Not available.

- Packing group: Not available.

- Environmental hazards: Not available.

- Special precautions for user: Not available.

- Transport in bulk according to IMO instruments: Not available.

Note: Transport classification may vary by mode and jurisdiction; confirm with carrier and applicable regulations.

SECTION 15: Regulatory information

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

- Regulatory listings (e.g., TSCA/REACH/DSL/IECSC/ENCS/AICS): Not available.
- GHS classification (jurisdiction-specific): Not available.

15.2 Chemical safety assessment

- No data available.

SECTION 16: Other information

SECTION 16: Other information

- Product name: Lemborexant
- Catalog No.: CS-CB-00056
- CAS No.: 1369764-02-2
- Supplier: Clearsynth Labs Ltd., Mumbai, India
- Emergency phone: +91-22-245045900

Disclaimer

- The information provided is believed to be accurate based on available data, but no warranty is expressed or implied. The user is responsible for determining suitability and for compliance with applicable laws and regulations.

Revision information

- Revision date: Not available.
- Version: Not available.

DISCLAIMER

This MSDS is system-generated. Please verify and confirm all data, statements, and values with the Support Team before use or distribution.